Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma
HER2, nectin-4, and TROP2 are preferentially expressed in the carcinomatous component of ECS. HER2-targeted antibody-drug conjugates may be a promising therapeutic strategy for ECS with serous carcinoma differentiation. Further investigation is warranted to determine the clinical relevance of targeting nectin-4 and TROP2 in ECS.
Authors
- Shih‐Yao Lin (ORCID: https://orcid.org/0000-0002-5367-2543)
- Ren‐Chin Wu (ORCID: https://orcid.org/0000-0003-1439-0874)
- Chiung‐Ru Lai
- Chung-Ting Chang
- Yi‐Jen Chen (ORCID: https://orcid.org/0000-0001-9281-1940)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Chang Gung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1016/j.gore.2025.101951
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00